Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.

ABSTRACT:

Purpose

Gastroesophageal adenocarcinoma (GEA) has a poor prognosis and few therapeutic options. Utilizing a 73-gene plasma-based next-generation sequencing (NGS) cell-free circulating tumor DNA (ctDNA-NGS) test, we sought to evaluate the role of ctDNA-NGS in guiding clinical decision-making in GEA.

Experimental design

We evaluated a large cohort (n = 2,140 tests; 1,630 patients) of ctDNA-NGS results (including 369 clinically annotated patients). Patients were assessed for genomic alteration (GA) distribution and correlation with clinicopathologic characteristics and outcomes.

Results

Treatment history, tumor site, and disease burden dictated tumor-DNA shedding and consequent ctDNA-NGS maximum somatic variant allele frequency. Patients with locally advanced dise

SUBMITTER: Maron SB 

PROVIDER: S-EPMC6891164 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature